Literature DB >> 9367864

Construction and enhanced cytotoxicity of a [cyanovirin-N]-[Pseudomonas exotoxin] conjugate against human immunodeficiency virus-infected cells.

T Mori1, R H Shoemaker, J B McMahon, R J Gulakowski, K R Gustafson, M R Boyd.   

Abstract

Cyanovirin-N (CV-N) is a novel 11-kDa anti-HIV(human immunodeficiency virus) protein that binds with high affinity to the viral envelope glycoprotein gp120. In contrast to soluble CD4 and most known neutralizing antibodies that bind gp120, CV-N exerts potent anti-viral activity against primary clinical HIV isolates as well as laboratory-adapted strains of HIV. Here we describe the recombinant production, purification, and characterization of a chimeric toxin molecule, FLAG-CV-N-PE38, that contains CV-N as a gp120-targeting moiety linked to the translocation and cytotoxic domains of Pseudomonas exotoxin A. FLAG-CV-N-PE38 showed enhanced cytotoxicity to HIV-infected, gp120-expressing H9 cells compared to uninfected H9 cells. Competition experiments with free CV-N provided further support that the enhanced FLAG-CV-N-PE38-induced cytotoxicity was due to interactions of the CV-N moiety with cell surface gp120. This study establishes the feasibility of use of CV-N as a gp120-targeting sequence for construction and experimental therapeutic investigations of unique new chimeric toxins designed to selectively destroy HIV-infected host cells.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9367864     DOI: 10.1006/bbrc.1997.7505

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.322


  4 in total

1.  Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120.

Authors:  M T Esser; T Mori; I Mondor; Q J Sattentau; B Dey; E A Berger; M R Boyd; J D Lifson
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

2.  Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells.

Authors:  T Mori; M R Boyd
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

Review 3.  An update of the recombinant protein expression systems of Cyanovirin-N and challenges of preclinical development.

Authors:  Hajie Lotfi; Roghayeh Sheervalilou; Nosratollah Zarghami
Journal:  Bioimpacts       Date:  2017-11-16

Review 4.  Plant made anti-HIV microbicides--a field of opportunity.

Authors:  Hester C T Lotter-Stark; Edward P Rybicki; Rachel K Chikwamba
Journal:  Biotechnol Adv       Date:  2012-06-28       Impact factor: 14.227

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.